Trial Profile

A Phase 1b/2a, Open Label Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104IAR in Adults With Eosinophilic Esophagitis (RESOLVE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2025 According to an Eupraxia Pharmaceuticals media release,clinical data from this study will be presented at key opinion leader (KOL) event on Friday, May 9, 2025 by Evan Dellon.
05 May 2025 According to an Eupraxia Pharmaceuticals media release, Eupraxia plans to disclose additional data periodically, additional long-term data to be released with higher doses in Q3 2025
05 May 2025 9-month data for Cohort 5 of the RESOLVE trial presented in the Eupraxia Pharmaceuticals Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com